Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases.
The company operates in the Therapeutics and Non-Therapeutics segments.
Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections.
The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity.
Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases.
The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas.
In addition, it is involved in the operation of medical clinics.
The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017.
Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 28, 23 | -2.22 Decreased by -684.21% | - |
| Sep 30, 22 | -0.05 Increased by +78.69% | -3.00 Increased by +98.33% |
| Apr 29, 22 | -0.25 Decreased by -232.35% | -3.30 Increased by +92.42% |
| Sep 15, 21 | -0.47 Decreased by -123.81% | -3.00 Increased by +84.33% |
| Apr 19, 21 | 0.38 Increased by +215.15% | -3.10 Increased by +112.26% |
| Mar 31, 21 | -0.23 Decreased by -126.45% | - |
| Dec 31, 20 | 0.19 Increased by +214.28% | - |
| Sep 1, 20 | -0.21 Increased by +32.26% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by -100.00% | -2.64 M Decreased by -40.24% | - - |
| Mar 31, 24 | N/A Increased by +100.00% | 2.66 M Increased by +219.77% | - - |
| Sep 30, 23 | 431.38 K Decreased by -32.36% | -5.49 M Increased by +65.88% | Decreased by -1.27 K% Increased by +49.55% |
| Mar 31, 23 | 768.43 K Decreased by -96.73% | -7.91 M Decreased by -126.55% | Decreased by -1.03 K% Decreased by -911.43% |
| Jun 30, 22 | 527.46 K Increased by +61.17% | -1.89 M Increased by +69.62% | Decreased by -357.42% Increased by +81.15% |
| Mar 31, 22 | -1.25 M Decreased by -524.87% | -2.22 M Increased by +76.84% | Increased by +177.14% Increased by +105.45% |
| Jun 30, 21 | 637.78 K Increased by +165.97% | -16.08 M Decreased by -76.94% | Decreased by -2.52 K% Increased by +33.47% |
| Mar 31, 21 | 23.49 M Increased by +6.03 K% | 29.81 M Increased by +301.00% | Increased by +126.93% Increased by +103.28% |